|Bid||26.50 x 800|
|Ask||26.90 x 1800|
|Day's Range||26.13 - 26.88|
|52 Week Range||11.05 - 26.89|
|Beta (3Y Monthly)||0.94|
|PE Ratio (TTM)||1,210.00|
|Earnings Date||Feb 17, 2020 - Feb 21, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.57|
Cancer testing firm NeoGenomics broke out Thursday from a flat base, a couple of days after reporting strong earnings. NEO is stock of the day. Many cancer-testing firms are doing well.STOCK MARKET TODAY is sponsored by Interactive Brokers. To open an account, go to ibkr.com/whyib
FT. MYERS, FL / ACCESSWIRE / November 6, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive ...
Anyone interested in NeoGenomics, Inc. (NASDAQ:NEO) should probably be aware that the President of Clinical Services...
NeoGenomics (NEO) delivered earnings and revenue surprises of 16.67% and 5.50%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
T hird-Quarter Highlights: Consolidated revenue increased 51% to $104.7 million Clinical Services revenue increased 56% to $92.6 million Pharma Services revenue increased 26% to $12.1 million Pharma Services ...
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of June 28. The results of that effort will be put on display in this article, as […]
NeoGenomics, Inc. (NASDAQ:NEO), which is in the life sciences business, and is based in United States, saw significant...
FT. MYERS, FL / ACCESSWIRE / October 1, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its Third quarter ...
FT. MYERS, FL / ACCESSWIRE / September 25, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, today announced that Bill Bonello, Chief Strategy and Corporate ...
NeoGenomics, Inc. (NASDAQ:NEO) shareholders have seen the share price descend 14% over the month. But in stark...
During Friday's Lightning Round of Mad Money one caller asked about the Fort Meyers, FL headquartered NeoGenomics : "I won't say no to anyone working to cure cancer," replied Jim Cramer. NeoGenomics is a clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. In this daily bar chart of NEO, below, we can see that prices more than doubled this calendar year.
The Morgan Stanley conference presentation will be webcast live and accessible online via the investors section of the Company’s website, www.neogenomics.com. NeoGenomics, Inc. specializes in cancer genetic testing and information services.
NEW YORK, NY / ACCESSWIRE / August 12, 2019 / Neo Performance Materials, Inc. (NASDAQ: NEO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 12, 2019 ...
FT. MYERS, FL / ACCESSWIRE / August 8, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, this morning filed an 8-K with the Securities and Exchange Commission ...
NeoGenomics stock is the IBD Stock Of The Day as the cancer-testing outlet breaks out on a never-higher relative strength line. Earlier this week, NeoGenomics posted a quarterly beat.
FORT MYERS, FL and WILMINGTON, NC / ACCESSWIRE / July 31, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetics testing services, and Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), announced the grand opening of a NeoGenomics oncology-focused clinical trials testing lab in the same building as the PPD® Laboratories central lab in Singapore. NeoGenomics’ Pharmaceutical Services Division has established a track record of rapid growth and is building a global network for clinical trials.
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and 5.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Second-Quarter Highlights: Consolidated revenue increased 50% to $101.7 million Clinical Services revenue increased 49% to $89.0 million Pharma Services revenue increased 55% to $12.7 million Pharma Services ...
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.